Ethaselen, also known as BBSKE, is a novel organoselenium thioredoxin reductase inhibitor, is currently being investigated in a phase I clinical trial in China. Ethaselen enhanced the efficacy of radiation therapy both in vivo and in vitro without observable toxicity. BBSKE was found to suppress irradiation-induced NF-κB activation dramatically when using A549 cells stably transfected with NF-κB luciferase reporter. Ethaselen is a potentially promising agent for the treatment of patients with NSCLC clinically.
CAS 217798-39-5 MFCD17798395
化学结构图
SMILES: O=c1c2ccccc2[se]n1CCn1[se]c2ccccc2c1=O
化学属性
| Mol. Weight | 422.2 |
|---|---|
| Appearance | white solid powder |
| Solubility | Soluble in DMSO, not in water |
别名和识别编码
| Chemical Name | Ethaselen, also known as BBSKE, is a novel organoselenium thioredoxin reductase inhibitor, is currently being investigated in a phase I clinical trial in China. Ethaselen enhanced the efficacy of radiation therapy both in vivo and in vitro without observable toxicity. BBSKE was found to suppress irradiation-induced NF-κB activation dramatically when using A549 cells stably transfected with NF-κB luciferase reporter. Ethaselen is a potentially promising agent for the treatment of patients with NSCLC clinically. |
|---|---|
| Formula | C16H12N2O2Se2 |
| Synonym | Ethaselen; EB; BBSKE. |
| IUPAC Name | 2,2'-(ethane-1,2-diyl)bis(benzo[d][1,2]selenazol-3(2H)-one) . |
| InChIKey | SFFSGPCYJCMDJM-UHFFFAOYSA-N |
| InChI | InChI=1S/C16H12N2O2Se2/c19-15-11-5-1-3-7-13(11)21-17(15)9-10-18-16(20)12-6-2-4-8-14(12)22-18/h1-8H,9-10H2 |
| Canonical SMILES | O=C1N(CCN2[Se]C3=CC=CC=C3C2=O)[Se]C4=CC=CC=C14 |
信息真实价格透明
资金保障
专业采购外包团队在线服务
信息真实价格透明
资金保障
专业采购外包团队在线服务
品牌质保精细包装
现货库存
一流品牌服务
产品应用
- Ethaselen, also known as BBSKE, is a novel organoselenium thioredoxin reductase inhibitor, is currently being investigated in a phase I clinical trial in China. Ethaselen enhanced the efficacy of radiation therapy both in vivo and in vitro without observable toxicity. BBSKE was found to suppress irradiation-induced NF-κB activation dramatically when using A549 cells stably transfected with NF-κB luciferase reporter. Ethaselen is a potentially promising agent for the treatment of patients with NSCLC clinically.
